![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
BPA (boronophenylalanine) is an engineered targeting boron pharmaceuticals to deliver the cellular precision and curative power of BNCT. It is being evaluated for the treatment of head and neck, brain, breast, melanoma and other cancers.
Lead Product(s): P-Borono-L-Phenylalanine
Therapeutic Area: Oncology Product Name: BAP
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2023
Details:
Under the agreement, Biddle will serve as the exclusive supplier of TC220, a proprietary boronated amino acid analog developed by TAE Life Sciences to support BNCT cancer treatment.
Lead Product(s): TC-220
Therapeutic Area: Oncology Product Name: TC220
Highest Development Status: IND Enabling Product Type: Large molecule
Recipient: Biddle Sawyer Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 15, 2023
Details:
TLS will provide support and training to HDX and intends to work with HDX to develop a local-language training and clinical education base in the future. BNCT is a combination treatment based on the reaction that occurs when a non-toxic compound containing boron-10.
Lead Product(s): BNCT
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: HDX Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 10, 2022
Details:
Results indicate that boron-11 concentrations of 80.4 ppm from sodium borocaptate (BSH) or 86.9 ppm from 4-borono-L-phenylalanine (BPA) treatments did not affect the biological effectiveness of proton beams due to proton–boron reactions in the DU145 prostate cancer cell line.
Lead Product(s): Proton Boron Capture-based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2022